|
Treatment Adherence and Virologic Response Over 48 Weeks Among Patients
Rapidly Initiating Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
(D/C/F/TAF) in the DIAMOND Study
|
|
|
Reported by Jules Levin
14TH INTERNATIONAL CONFERENCE ON HIV TREATMENT AND PREVENTION ADHERENCE; JUNE 17-19, 2019; MIAMI, FLORIDA
Hélène Hardy,1,* Donghan Luo,2 Debra Israel,1 Richard Bruce Simonson,1 Keith Dunn1
1Janssen Scientific Affairs, LLC, Titusville, NJ; 2Janssen Research & Development, LLC, Titusville, NJ.
![0801191](../images/080119/080119-1/0801191.gif)
![0801192](../images/080119/080119-1/0801192.gif)
![0801193](../images/080119/080119-1/0801193.gif)
![0801194](../images/080119/080119-1/0801194.gif)
![0801195](../images/080119/080119-1/0801195.gif)
![0801196](../images/080119/080119-1/0801196.gif)
![0801197](../images/080119/080119-1/0801197.gif)
![0801198](../images/080119/080119-1/0801198.gif)
![0801199](../images/080119/080119-1/0801199.gif)
![08011910](../images/080119/080119-1/08011910.gif)
![08011911](../images/080119/080119-1/08011911.gif)
|
|
|
|
|
|
|